Allogene (ALLO) Q2 2026 Earnings Call Transcript

Allogene (ALLO) reported a Q2 2026 net loss of $42.7M, or $0.13 per share, with $4.6M in collaboration revenue. Cash reserves totaled $423.6M, providing a runway into 2029. Key clinical updates include 58.3% MRD negativity in the ALPHA3 trial and a 31% ORR for ALLO-316. The company aims to expand access to CAR T therapies in community settings. FDA granted RMAT and Fast Track designations for cema-cel. Management highlighted upcoming milestones and risks, including small data sets and safety cha

Original reporting
Published Aug 19, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 9:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Allogene (ALLO) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$ALLONeutralMed
01

Why it matters

The disclosed cash position reduces near‑term financing risk, while the net loss underscores the need for successful trial outcomes to drive future revenue.

02

Market read

Earnings release provides fresh data for traders; the cash runway and trial milestones are the primary catalysts.

03

What to watch

Upcoming Phase 2 ALPHA3 data and RMAT designation could materially shift valuation if results are positive.

Relevance 8/10Novelty 8/10Timing: after market close

Background

Allogene Therapeutics (ALLO) provided its Q2 2026 earnings via a conference call, highlighting financials, trial updates, and regulatory designations.

Company-level read

Ticker impact

$ALLONeutralHigh confidence
Context

Q2 2026 earnings call disclosed a $42.7M net loss, $423.6M cash runway to 2029, and FDA RMAT/Fast Track designations for its lead CAR‑T candidate.

Expected impact

Potential short‑term upside if investors view the cash runway positively; downside risk if loss magnitude or trial timelines disappoint.

Evidence & confidence

Biotech earnings with cash runway extensions often trigger modest price moves; the magnitude of loss is typical for a pre‑revenue company, so market reaction will hinge on trial milestones.

Market effects

Allogene's cash runway extension may reassure investors in the broader cell‑therapy sector.

Limited to US biotech investors; no broader regional effect.

Minimal global impact beyond niche oncology investors.

Counterpoint

The cash runway may mask underlying execution risk; investors could short on the basis of continued losses.

Key entities

  • Allogene Therapeutics

    US‑listed biotech developing allogeneic CAR‑T therapies.

  • Zachary Roberts

    President and CEO of Allogene Therapeutics.

Related articles

$ALLOMed

Allogene Therapeutics Reports Third Quarter 2026 Financial Results and Business Update

Allogene Therapeutics, Inc. (ALLO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Allogene Therapeutics Reports Third Quarter 2026 Financial Results and Business Update • Pivotal Phase 2 ALPHA3 Program in 1L Large B-cell Lymphoma (LBCL): ◦ ALPHA3 Enrollment Momentum Continues, Supported by Expanding Trial Network, Increased MRD Screening, and Bris

$ALLOMed

Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs

Allogene Therapeutics (ALLO) reported Q2 2026 EPS loss of 13 cents, narrower than the Zacks Consensus loss of 16 cents, helped by lower R&D costs. Collaboration revenue from related parties was $4.6 million. Cash, cash equivalents and investments rose to $423.6 million after a $200.4 million April offering. The company reiterated 2026 operating expense guidance and expects ALPHA3 interim EFS data in mid-2027.

$ALLOMed

Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update

Allogene Therapeutics, Inc. (ALLO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update • Pivotal Phase 2 ALPHA3 Program in 1L Large B-cell Lymphoma (LBCL): ◦ Recent Interim Futility Analysis Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatien

$PANWHighAI 9/10

Palo Alto Networks Reports Fiscal First Quarter 2027 Financial Results

Palo Alto Networks Inc (PANW) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Palo Alto Networks Reports Fiscal First Quarter 2027 Financial Results SANTA CLARA, Calif., Nov. 18, 2026 — Palo Alto Networks ® (NASDAQ: PANW), the global AI cybersecurity leader, announced today financial results for its fiscal first quarter ended October 31, 2026.

$IPARMedAI 8/10

INTERPARFUMS, INC. ANNOUNCES FULL YEAR 2027 GUIDANCE

INTERPARFUMS INC (IPAR) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 FOR IMMEDIATE RELEASE INTERPARFUMS, INC. ANNOUNCES FULL YEAR 2027 GUIDANCE New York, New York, November 18, 2026, Interparfums, Inc. (NASDAQ GS: IPAR) (“Interparfums” or the “Company”) today announced initial guidance for its fiscal year ending December 31, 2027. In